Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
1.480
-0.080 (-5.14%)
Nov 21, 2024, 11:48 AM EST - Market open
Cellectar Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CLRB stock have an average target of 20, with a low estimate of 12 and a high estimate of 28. The average target predicts an increase of 1,251.35% from the current stock price of 1.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CLRB stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $12 | Buy | Maintains | $14 → $12 | +710.81% | Nov 19, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $14 | Buy | Reiterates | $14 | +845.95% | Oct 11, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $20 → $28 | Strong Buy | Maintains | $20 → $28 | +1,791.89% | Mar 28, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 → $12 | Buy | Reiterates | $11 → $12 | +710.81% | Mar 28, 2024 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +1,251.35% | Mar 4, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
52.41M
EPS This Year
-1.81
from -3.50
EPS Next Year
-0.73
from -1.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 124.3M | 194.9M | ||
| Avg | n/a | 52.4M | 114.9M | ||
| Low | n/a | 13.7M | 71.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 271.9% | ||
| Avg | - | - | 119.3% | ||
| Low | - | - | 36.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.45 | 0.47 | 1.07 | ||
| Avg | -1.81 | -0.73 | 0.16 | ||
| Low | -1.91 | -1.27 | -0.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.